{"product_id":"collaborative-innovation-in-drug-discovery-isbn-9780470917374","title":"Collaborative Innovation in Drug Discovery","description":"\u003cb\u003eCan academia save the pharmaceutical industry?\u003c\/b\u003e  \u003cp\u003eThe pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R\u0026amp;D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. \u003ci\u003eCollaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships\u003c\/i\u003e provides insight into the potential synergy of basing R\u0026amp;D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eGain global perspectives on the benefits and potential issues surrounding collaborative innovation\u003c\/li\u003e \u003cli\u003eDiscover how industries can come together to prevent another \"Pharma Cliff\"\u003c\/li\u003e \u003cli\u003eLearn how nonprofits are becoming the driving force behind innovation\u003c\/li\u003e \u003cli\u003eRead case studies of specific academia-pharma partnerships for real-life examples of successful collaboration\u003c\/li\u003e \u003cli\u003eExplore government initiatives that help foster cooperation between industry and academia\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eDr. Chaguturu’s thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In \u003ci\u003eCollaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships\u003c\/i\u003e, he and his expert team provide insight into the various nuances of the debate.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eForeword xv\u003c\/b\u003e\u003cbr\u003e by \u003ci\u003eFerid Murad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePreface xix\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAbout the Book xxv\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAbout the Editor xxvii\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eContributors xxix\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1\u003cbr\u003e \u003ci\u003eIf I have seen further it is by standing on the shoulders of giants.\u003c\/i\u003e\u003cbr\u003e \u003ci\u003e—Isaac Newton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3\u003cbr\u003e \u003ci\u003eWyatt R. Hume\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 DIVIDED WE FALL 11\u003cbr\u003e \u003ci\u003eWilliam B. Mattes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY 21\u003cbr\u003e \u003ci\u003eJames M. Shaeffer and Sarah MacDonald\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31\u003cbr\u003e \u003ci\u003eLitao Zhang and Carl Decicco\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISK\u003cbr\u003e PRECOMPETITIVE INITIATIVES 57\u003cbr\u003e \u003ci\u003eAnuradha Roy and Rathnam Chaguturu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE CHALLENGES 75\u003cbr\u003e \u003ci\u003eChristopher A. Lipinski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVE COLLABORATION 85\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGovernments will always play a huge part in solving big problems. . . .\u003c\/i\u003e\u003cbr\u003e \u003ci\u003eThey also fund basic research, which is a crucial component of the innovation that improves life for everyone. —Bill Gates\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 THE VALUE OF UNIVERSITY–INDUSTRY PARTNERSHIPS 87\u003cbr\u003e \u003ci\u003eAnthony M. Boccanfuso\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCH APPROACHES 99\u003cbr\u003e \u003ci\u003eMark A. Scheideler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115\u003cbr\u003e \u003ci\u003eKate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P. Guo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC–PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCE CANCER THERAPY 135\u003cbr\u003e \u003ci\u003eJason V. Cristofaro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159\u003cbr\u003e \u003ci\u003eJohn Watson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY IMPASSE 173\u003cbr\u003e \u003ci\u003eBhushan Patwardhan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF 195\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eComing together is a beginning, staying together is progress, and working together is success. —Henry Ford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION 197\u003cbr\u003e \u003ci\u003eBernard H. Munos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213\u003cbr\u003e \u003ci\u003eValentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221\u003cbr\u003e \u003ci\u003eAssem S. el Baghdady and Yasser M.S. el Baghdady\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255\u003cbr\u003e \u003ci\u003eMonika Lessl and Khusru Asadullah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 CLOSE CONTACT: A COLOCATION MODEL FOR ACADEMIC–INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267\u003cbr\u003e \u003ci\u003ePeter A. Covitz and Terrence D. Ruddy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA–INDUSTRY PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE BAYER–UNIVERSITY OF COLOGNE “PRIVILEGED PARTNERSHIP” 279\u003cbr\u003e \u003ci\u003eStefan Herzig, Marion Rozowski, and Ingo Flamme\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUG DISCOVERY 303\u003cbr\u003e \u003ci\u003eBarry A. Bunin and Sean Ekins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY 319\u003cbr\u003e \u003ci\u003ePaul R. Eynott and Carole Fages\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341\u003cbr\u003e \u003ci\u003eAllen B. Reitz and Kathleen M. Czupich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 CHEMICAL CONSULTING 355\u003cbr\u003e \u003ci\u003eLester A. Mitscher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION 367\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCan’t afford to innovate? Open up! —Henry Chesbrough\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369\u003cbr\u003e \u003ci\u003eTonny Johnson and Sanchayita Kar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH 385\u003cbr\u003e \u003ci\u003eGali Hagel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON’S DISEASE 411\u003cbr\u003e \u003ci\u003eAllan J. Tobin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437\u003cbr\u003e \u003ci\u003eSpencer L. Shorte\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC 451\u003cbr\u003e \u003ci\u003eThomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and Michael R. Jackson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V: ACADEMIC SCREENING CENTERS COME OF AGE 487\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eOpen access high-throughput drug discovery in the public domain is a Mount Everest in the making. —Rathnam Chaguturu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING CENTERS 489\u003cbr\u003e \u003ci\u003eNathan S. Blow\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499\u003cbr\u003e \u003ci\u003ePhilip Gribbon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517\u003cbr\u003e \u003ci\u003eHorst Flotow and Alex Matter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533\u003cbr\u003e \u003ci\u003eDavid Camp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEverything that can be invented has been invented. —Charles Duell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565\u003cbr\u003e \u003ci\u003eAssem S. el Baghdady\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUG DISCOVERIES 577\u003cbr\u003e \u003ci\u003eChristopher Paschall\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609\u003cbr\u003e \u003ci\u003eDonna Marie De Carolis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART VII: THE FINAL FRONTIER 621\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eNo one can whistle a symphony; it takes a whole orchestra to play it.\u003c\/i\u003e\u003cbr\u003e \u003ci\u003e—Halford E. Luccock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE TRANSLATIONAL SCIENCE AND PUBLIC–PRIVATE COLLABORATION 623\u003cbr\u003e \u003ci\u003eIbis Sánchez-Serrano\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION IN BIOMEDICINE 653\u003cbr\u003e \u003ci\u003eElizabeth Iorns\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663\u003cbr\u003e \u003ci\u003eDeborah E. Collyar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 TO LEASH OR UNLEASH THE POWER OF PUBLIC–PRIVATE COLLABORATION: IN HEALTH AND DISEASE 679\u003cbr\u003e \u003ci\u003eHakim Djaballah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIndex 687\u003c\/i\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eRATHNAM CHAGUTURU, P\u003csmall\u003eH\u003c\/small\u003eD,\u003c\/b\u003e is the Founder \u0026amp; CEO of iDDPartners, a nonprofit think-tank focused on pharmaceutical innovation. He has more than thirty years of experience in executing new lead discovery projects and forging discovery partnerships. He is the Founding President of the International Chemical Biology Society and Editor-in-Chief of \u003ci\u003eCombinatorial Chemistry and High Throughput Screening\u003c\/i\u003e. He serves on several other editorial and scientific advisory boards along with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national and international conferences, passionately advocating the virtues of collaborative partnerships in addressing the pharmaceutical innovation crisis.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eSets the stage for a new, improved paradigm in drug discovery\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDespite spending more than $135 billion annually on R\u0026amp;D, the pharmaceutical industry faces an innovation crisis. Given the complexities and the expense of R\u0026amp;D, this book argues that we can accomplish much more—with greater efficiency and less cost—when private and public sectors collaborate, each focusing on their core strengths.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCollaborative Innovation in Drug Discovery\u003c\/i\u003e focuses on the early stage of drug discovery, the most critical barrier to delivering a steady flow of viable drug candidates into the pipeline. The book assesses the current state of drug discovery in the pharmaceutical industry, government, non-profit, and academia, identifying the areas where each sector excels and areas where gaps exist. Next, the authors explore ways these sectors can establish mutually beneficial partnerships in order to discover, develop, and bring to market improved, safer drugs to treat human diseases. Topics include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eStatus of healthcare and unmet medical needs\u003c\/li\u003e \u003cli\u003eBiomedical research environment, drug discovery efforts, and market risks in industry and academia\u003c\/li\u003e \u003cli\u003eNIH Roadmap and EU-OpenScreen initiatives\u003c\/li\u003e \u003cli\u003eTrends in academia-pharmaceutical partnerships, including case studies\u003c\/li\u003e \u003cli\u003eDrug repositioning, open source partnerships, and challenges and practices for conducting clinical trials\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eEditor Rathnam Chaguturu has assembled a panel of expert authors from around the world, representing all the sectors involved in drug discovery. Their contributions are not only based on a thorough review of the current literature, but also their own first-hand experience of what works and what doesn’t.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCollaborative Innovation in Drug Discovery\u003c\/i\u003e offers pharmaceutical scientists and managers working in both private and public sectors a new, more productive road map to discover drugs that the world needs.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988944732389,"sku":"NP9780470917374","price":156.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470917374.jpg?v=1761782153","url":"https:\/\/k12savings.com\/es\/products\/collaborative-innovation-in-drug-discovery-isbn-9780470917374","provider":"K12savings","version":"1.0","type":"link"}